Skip to main content
SpringerLink
Log in

Prostate cancer screening (United States)

  • Perspective
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

In 1995, there will be 244,000 new cases of prostate cancer, and 40,400 deaths from prostate cancer, among men in the United States. The American Cancer Society reports that the incidence rate of prostate cancer is increasing at an accelerated pace, and was 21 percent higher in 1994 than in 1993. The major reason for this steep rise is likely to be due to increased popularity of prostate cancer screening which, by identifying latent, asymptomatic cases, may convert them into clinical cases. Is screening—an important means of cancer control for many sites—a reasonable approach for prostate cancer control? The answer is not straightforward because prostate cancer is not one, but three diseases: a latent form which will cause no harm; a progressive form which will become symptomatic and can kill; and a rapidly progressive form so malignant that it is likely to kill, whether detected early or late. Screen-detection may be worthwhile only for the second form, as tumors of the first form need never be detected, and tumors of the third form progress so rapidly that timely screen-detection is nearly impossible and, if accomplished, may be valueless. As there is no way to differentiate among the three diseases when screening, the possible deleterious effects of screen-detection must be weighed against the benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Trends in prostate cancer-United States, 1980–1988. MMWR 1992; 41: 401–4.

  2. Garfinkel L. Evaluating cancer statistics. CA Cancer J Clin 1994; 44: 5–6.

    Google Scholar 

  3. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8–30.

    Google Scholar 

  4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–54.

    Google Scholar 

  5. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin 1993; 43: 134–49.

    Google Scholar 

  6. Cooner WH. Prostate cancer detection: a practical approach. Prim Care Cancer 1993: 25–8.

  7. Chodak GW. Questioning the value of screening for prostate cancer in asymptomatic men. Urology 1993; 42: 116–8.

    Google Scholar 

  8. Brawer MK, Catalona WJ, McConnell JD. Prostate cancer: Is screening the answer? Patient Care 1992; 26: 55–8; 61–3; 67–8.

    Google Scholar 

  9. Fracchia JA. Costs and other aspects of screening vs early detection of prostate cancer. Prim Care Cancer 1993; 13: 31–2.

    Google Scholar 

  10. Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 1993: 105–11.

  11. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–4.

    Google Scholar 

  12. Miller BA, Hayes RB, Potosky AL, Brawley O, Kaplan R. SEER Cancer Statistics Review: 1973–1990. Bethesda, MD (USA) National Cancer Institute, 1993; NIH Pub. No. 93–2789: XXII.1, XXII.2.

    Google Scholar 

  13. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977; 20: 680–8.

    Google Scholar 

  14. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: Incidence, histology and morphometric observations. J Urol 1989; 141: 1091–4.

    Google Scholar 

  15. Halpert B, Schmalhorst WR. Carcinoma of the prostate in patients 70 to 79 years old. Cancer 1966; 19: 695–8.

    Google Scholar 

  16. Zaridze DG, Boyle P. Cancer of the prostate: epidemiology and aetiology. Br J Urol 1987; 59: 493–502.

    Google Scholar 

  17. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603–16.

    Google Scholar 

  18. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989; 16: 635–55.

    Google Scholar 

  19. Schottenfeld D, Fraumeni JFJr. Cancer Epidemiology and Prevention. Philadelphia, PA (USA): W. B. Saunders Company, 1982: 938.

    Google Scholar 

  20. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991; 13: 200–27.

    Google Scholar 

  21. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793–803.

    Google Scholar 

  22. Gorman C. The private pain of prostate cancer. Time 1992; 140: 77–80.

    Google Scholar 

  23. Dittman RE. Help for the disease men fear most. Read Dig 1992; 141: 209–10, 212–4, 216.

    Google Scholar 

  24. Gallo N. Prostate problems: What every man needs to know. Bet Hom and Gard 1993; 71: 72, 74–6.

    Google Scholar 

  25. Lax E. Prostate cancer: Lifesaving advances. Family Circle 1993; 106: 64.

    Google Scholar 

  26. What if it's cancer? Consum Rep 1993; 58: 463–5.

  27. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. Ca Cancer J Clin 1993; 43: 42–6.

    Google Scholar 

  28. Cole P, Morrison AS. Basic issues in population screening for cancer. JNCI 1980; 64: 1263–72.

    Google Scholar 

  29. Baran GW, Golin AL, Bergsma CJ, et al. Biologic aggressiveness of palpable and monpalpable prostate cancer: assessment with endosonography. Radiology 1991; 178: 201–6.

    Google Scholar 

  30. Grizzle WE, Myers RB, Arnold MM, Srivastava S. Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem 1994; 19: 259–66.

    Google Scholar 

  31. Ries LAG, Hankey BF, Miller BA, Hartman AM, Adwards BK. Cancer Statistics Review, 1973–88. Bethesda, MD (USA): National Cancer Institute, 1991; NIH Pub. No. 91–2789: II.45, III.41.

    Google Scholar 

  32. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742–6.

    Google Scholar 

  33. US Department of Health and Human Services. Vital Statistics of the United States, 1989. Life Tables. Hyattsville, MD (USA): DHHS, 1992; DHHS Pub. No. (PHS) 93–1104, Vol. II, Section 6: Table 6–3, p 12.

    Google Scholar 

  34. Centers for Disease Control and Prevention. Monthly Vital Statistics Report 1991; 38: 13 (Table 4. Estimated deaths and death rates, by age, race, and sex: United States, 1990).

  35. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993; 269: 61–4.

    Google Scholar 

  36. Schmidt JD, Mettlin CJ, Natarajan N, et al. Trends and patterns of care for prostate cancer, 1974–1983: Results of surveys by the American College of Surgeons. J Urol 1986; 136: 416–21.

    Google Scholar 

  37. Friedman GD, Hiatt RA, Quesenberry CP, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337: 1526–9.

    Google Scholar 

  38. Chadwick DJ, Kemple T, Astley JP, et al. Pilot study of screening for prostate cancer in general practice. Lancet 1991; 338: 613–6.

    Google Scholar 

  39. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860–4.

    Google Scholar 

  40. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289–94.

    Google Scholar 

  41. Chodak GW. Transrectal ultrasonography: Is it ready for routine use? JAMA 1988; 259: 2744–5.

    Google Scholar 

  42. Littrup PJ, Lee F, Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin 1992; 42: 198–211.

    Google Scholar 

  43. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129–35.

    Google Scholar 

  44. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650–8.

    Google Scholar 

  45. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient reported complications and follow-up treatment after radical prostatectomy. The national medicate experience: 1988–1990 (updated June 1993). Urology 1993; 42: 622–9.

    Google Scholar 

  46. Lax E. Is your husband dying of embarrassment? The truth about prostate cancer. Family Circle 1993; 106: 57–8, 62, 140.

    Google Scholar 

  47. Lubke WL, Optenberg SA, Thompton IM. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. JNCI 1994; 86: 1790–2.

    Google Scholar 

  48. Garnick MB. The dilemmas of prostate cancer. Sci Am 1994; 270: 72–81.

    Google Scholar 

  49. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. JAMA 1994; 272: 773–80.

    Google Scholar 

  50. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. Urology 1994; 152: 1910–4.

    Google Scholar 

Download references

Authors
  1. John W. Waterbor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anton J. Bueschen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dr Waterbor is with the Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, AL, USA. Dr Bueschen is with the Division of Urology, Department of Surgery, School of Medicine, University of Alabama at Birmingham. Address correspondence to Dr Waterbor, University of Alabama at Birmingham, Department of Epidemiology, Tidwell Hall 201, 720 S 20th Street, Birmingham, AL 35924-0008, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waterbor, J.W., Bueschen, A.J. Prostate cancer screening (United States). Cancer Causes Control 6, 267–274 (1995). https://doi.org/10.1007/BF00051798

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051798

Key words

Search

Navigation